Navigation Links
MediPoint: Total Hip Replacement - APAC Analysis and Market Forecasts
Date:11/7/2013

SPA) 134
Figure 52: Cemented and Cementless Stems (Medacta) 136
Figure 53: Helicon Hip System (TGM Medical wholly owned by Medtronic) 139
Figure 54: Vektor-Titan and Vektor-CoCr (Peter Brehm GMBH) 141
Figure 55: Libra and Sagitta EVL (Serf Dedienne Santé) 143
Figure 56: Acetabular Cups (Serf Dedienne Santé) 145
Figure 57: Echelon and Synergy (Smith & Nephew) 147
Figure 58: Anthology Hip System (Smith & Nephew) 149
Figure 59: CPCS and Spectron Hip System (Smith & Nephew) 150
Figure 60: Emperion and SMF Modular Stems (Smith & Nephew) 152
Figure 61: Acetabular Cups (Smith & Nephew) 153
Figure 62: ProClass Hip Stem (Stelkast) 154
Figure 63: Progeny Hip Stem (Stelkast) 156
Figure 64: Protract Hip Stem (Stelkast) 157
Figure 65: Provident Hip Stem (Stelkast) 159
Figure 66: Acetabular Systems (Stelkast) 161
Figure 67: Cementless Stems (Stryker) 163
Figure 68: Cemented Stems (Stryker) 165
Figure 69: Acetabular Systems (Stryker) 166
Figure 70: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 167
Figure 71: Linea Stem (Tornier N.V.) 169
Figure 72: Meije Duo Stem (Tornier N.V.) 171
Figure 73: Oceane Stem (Tornier N.V.) 173
Figure 74: Tornier Femoral Heads (Tornier N.V.) 175
Figure 75: Oceane Cup (Tornier N.V.) 176
Figure 76: Tornier Dynacup (Tornier N.V.) 178
Figure 77: Tornier Dual Mobility (Tornier N.V.) 179
Figure 78: Perfecta Cementless and Cemented Stems (Wright Medical) 180
Figure 79: Cementless Femoral Stems (Wright Medical) 182
Figure 80: Profemur Gladiator (Wright Medical) 184
Figure 81: Acetabular Systems (Wright Medical) 185
Figure 82: UTF and UTF Reduced Stem (United Orthopedic Corporation) 187
Figure 83: Hip U1 and U2 Stems (United Orthopedic Corporation) 188
Figure 84: Acetabular Systems (U
'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. MediPoint: Total Hip Replacement - EU Analysis and Market Forecasts
2. MediPoint: In-Vitro Colorectal Cancer Screening Tests - APAC Analysis and Market Forecasts
3. MediPoint: In-Vitro Colorectal Cancer Screening Tests - US Analysis and Market Forecasts
4. MediPoint: In-Vitro Colorectal Cancer Screening Tests - EU Analysis and Market Forecasts
5. MediPoint: Hernia Repair - South American Analysis and Market Forecasts
6. MediPoint: Total Hip Replacement - US Analysis and Market Forecasts
7. MediPoint: Hernia Repair - APAC Analysis and Market Forecasts
8. MediPoint: Hernia Repair - EU Analysis and Market Forecasts
9. MediPoint: Hernia Repair - US Analysis and Market Forecasts
10. Total hospital cost of robotic or conventional open-chest mitral valve repair surgery is similar
11. Upgraded Dragon Medical Practice Edition 2 Being Offered by Total Voice Technologies with Special Pricing Incentive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... End-of-life aspects, the corresponding terminology, and the relevance ... considered in publications on randomized controlled trials (RCTs). ... the German Institute for Quality and Efficiency in ... as final report. , Together with external experts, ... examples: glioblastoma, lung cancer, malignant melanoma, and pancreatic ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... An Oregon State University researcher has found a relationship ... symptoms of autism spectrum disorder in very young children. ... first to show a direct relationship between motor skills ... gross motor skills should be included in treatment plans ... assistant professor in OSU,s College of Public Health and ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... ... University Edwardsville School of Pharmacy has been awarded -- along with the Saint ... (NIH) grant to study ways of relieving chronic pain through new approaches in treating ... ...
... Kimberly-Clark Corporation (NYSE: KMB ) has joined forces ... performance of some of its product packaging. The new ... which benefit schools and communities nationwide. , Kimberly-Clark, ... health, hygiene, and well being, and TerraCycle are now ...
... Life ... , ... 2009 -- Life Care Centers of America recently named Michael Lops as its ... Care, succeeds Sharon Coleman in the position. His appointment is based on “his extensive experience ...
... , MONDAY, Nov. 2 (HealthDay News) -- Though someone ... lack basic knowledge about the potentially life-threatening disease, according ... , Diabetes is responsible for more deaths each year ... combined, but just 42 percent of those surveyed knew ...
... , ROCKVILLE, Md., Nov. 2 Vanda Pharmaceuticals Inc. (Vanda) ... development and commercialization of clinical-stage products for central nervous system ... quarter ended September 30, 2009. , Vanda reported ... of 2009, compared to $12.4 million for the second quarter ...
... , Preliminary evaluation after completion of ... endpoint has been met for patients with advanced-stage, ... Nov. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; ... company focused on endocrine therapy and oncology, today announced ...
Cached Medicine News:Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 2Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 3Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 4Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 2Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 3Health News:Lops named Life Care's New Chief Compliance Officer 2Health News:Americans Get Failing Grade on Diabetes Awareness 2Health News:Americans Get Failing Grade on Diabetes Awareness 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 2Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 4Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 5Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 6Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 7Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 8Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 9Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 10Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 11Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 12Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... 2012  JARVIK HEART, Inc., a privately-held company that develops ... of its Pivotal Trial for evaluation of the Jarvik ... device for DT means that it will provide long-term, ... are not candidates for heart transplant. The approval permits ...
... Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... and marketer of medical devices worldwide, announced today its ... full year ended December 31, 2011. ... Fourth quarter net revenue increased 25.2% year-over-year ...
Cached Medicine Technology:JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 2JARVIK HEART Announces FDA Conditional Approval of Trial Using the Jarvik 2000® Heart for Destination Therapy 3Mindray Announces 2011 Fourth Quarter and Full Year Results 2Mindray Announces 2011 Fourth Quarter and Full Year Results 3Mindray Announces 2011 Fourth Quarter and Full Year Results 4Mindray Announces 2011 Fourth Quarter and Full Year Results 5Mindray Announces 2011 Fourth Quarter and Full Year Results 6Mindray Announces 2011 Fourth Quarter and Full Year Results 7Mindray Announces 2011 Fourth Quarter and Full Year Results 8Mindray Announces 2011 Fourth Quarter and Full Year Results 9Mindray Announces 2011 Fourth Quarter and Full Year Results 10Mindray Announces 2011 Fourth Quarter and Full Year Results 11Mindray Announces 2011 Fourth Quarter and Full Year Results 12Mindray Announces 2011 Fourth Quarter and Full Year Results 13Mindray Announces 2011 Fourth Quarter and Full Year Results 14Mindray Announces 2011 Fourth Quarter and Full Year Results 15Mindray Announces 2011 Fourth Quarter and Full Year Results 16Mindray Announces 2011 Fourth Quarter and Full Year Results 17
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: